デフォルト表紙
市場調査レポート
商品コード
1668061

CRISPRゲノム治療市場- 世界の産業規模、シェア、動向、機会、予測、疾患タイプ別、治療タイプ別、投与方法別、エンドユーザー別、標的遺伝子改変別、地域別、競合別、2020～2030年

Crispr Genomic Cure Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Therapy Type, By Delivery Method, By End User, By Targeted Genetic Modification, By Region & Competition, 2020-2030F

出版日
ページ情報
英文 180 Pages
納期
2～3営業日
カスタマイズ可能
CRISPRゲノム治療市場- 世界の産業規模、シェア、動向、機会、予測、疾患タイプ別、治療タイプ別、投与方法別、エンドユーザー別、標的遺伝子改変別、地域別、競合別、2020～2030年
出版日: 2025年02月28日
発行: TechSci Research
ページ情報: 英文 180 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

CRISPRゲノム治療の世界市場規模は2024年に29億5,000万米ドルとなり、2030年のCAGRは25.15%で、予測期間中に目覚ましい成長が予測されています。

世界のCRISPRゲノム治療市場は、バイオテクノロジーと医療産業の中で急速に発展しているセグメントです。CRISPR（Clustered Regularly Interspaced Short Palindromic Repeats）技術は遺伝子編集に革命をもたらし、様々な遺伝病や遺伝性疾患の治療に大きな可能性を秘めています。

市場概要
予測期間 2026～2030年
市場規模：2024年 29億5,000万米ドル
市場規模：2030年 113億6,000万米ドル
CAGR：2025～2030年 25.15%
急成長セグメント 遺伝性疾患
最大市場 北米

市場促進要因

遺伝性疾患と慢性疾患の有病率の増加

主要市場課題

倫理的・規制的ハードル

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 CRISPRゲノム治療市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 疾患タイプ別（遺伝性疾患、がん、感染症、神経疾患、心血管疾患、血液疾患、代謝疾患、その他）
    • 治療タイプ別（遺伝子編集、遺伝子治療、細胞治療、免疫療法）
    • 投与方法別（生体内、生体外）
    • エンドユーザー別（病院クリニック、研究機関、バイオテクノロジー・製薬会社）
    • 標的遺伝子改変別（単一遺伝子改変、複数遺伝子改変、ゲノムワイド改変）
    • 地域別
    • 企業別（2024年）
  • 市場マップ

第6章 北米のCRISPRゲノム治療市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州のCRISPRゲノム治療市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋のCRISPRゲノム治療市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米のCRISPRゲノム治療市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカのCRISPRゲノム治療市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 製品上市
  • 合併と買収

第13章 世界のCRISPRゲノム治療市場：SWOT分析

第14章 競合情勢

  • Merck KGaA
  • Takara Bio Inc
  • Lonza Group AG
  • Horizon Discovery Group Ltd
  • Genscript BIoTech Corp
  • Synthego Corp
  • Precision BioSciences Inc
  • Mammoth Biosciences Inc
  • Thermo Fisher Scientific Inc
  • Intellia Therapeutics Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 17664

Global Crispr Genomic Cure Market was valued at USD 2.95 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 25.15% through 2030. The global CRISPR genomic cure market is a rapidly evolving sector within the biotechnology and healthcare industries. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionized gene editing and holds immense promise for treating various genetic and hereditary diseases.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.95 Billion
Market Size 2030USD 11.36 Billion
CAGR 2025-203025.15%
Fastest Growing SegmentGenetic Disorders
Largest MarketNorth America

Key Market Drivers

Increasing Prevalence of Genetic Disorders and Chronic Diseases

The growing incidence of genetic disorders and chronic diseases is a major driver behind the rapid expansion of the Global CRISPR Genomic Cure Market. Genetic disorders and congenital abnormalities affect approximately 2%-5% of all live births, contributing to up to 30% of pediatric hospital admissions and accounting for nearly 50% of childhood mortality in industrialized nations. These figures highlight a critical demand for advanced genomic interventions, positioning CRISPR-based therapies as a transformative solution in pediatric healthcare. As the burden of hereditary and chronic illnesses continues to rise worldwide, there is an increasing demand for innovative, targeted, and long-term solutions to treat these conditions. CRISPR-based gene editing has emerged as a groundbreaking approach, offering precise and potentially curative treatments for diseases with a strong genetic basis. The incidence of genetic disorders and chronic diseases is increasing due to factors such as aging populations, environmental influences, and inherited genetic mutations. Annually,

Key Market Challenges

Ethical and Regulatory Hurdles

Perhaps one of the most significant challenges is the ethical and regulatory landscape surrounding CRISPR technology. The ethical debate over gene editing in humans, particularly germline editing, remains a contentious issue. Regulatory agencies worldwide are grappling with the need to strike a balance between fostering innovation and ensuring safety and ethical considerations.

Key Market Players

  • Merck KGaA
  • Takara Bio Inc
  • Lonza Group AG
  • Horizon Discovery Group Ltd
  • Genscript Biotech Corp
  • Synthego Corp
  • Precision BioSciences Inc
  • Mammoth Biosciences Inc
  • Thermo Fisher Scientific Inc
  • Intellia Therapeutics Inc

Report Scope:

In this report, the Global Crispr Genomic Cure Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Crispr Genomic Cure Market, By Disease Type:

  • Genetic Disorders
  • Cancer
  • Infectious Diseases
  • Neurological Disorders
  • Cardiovascular Disorders
  • Blood Disorders
  • Metabolic Disorders
  • Others

Crispr Genomic Cure Market, By Therapy Type:

  • Gene Editing
  • Gene Therapy
  • Cell Therapy
  • Immunotherapy

Crispr Genomic Cure Market, By Delivery Method:

  • In vivo
  • Ex vivo

Crispr Genomic Cure Market, By End User:

  • Hospitals & Clinics
  • Research Institutes
  • Biotechnology & Pharmaceutical Companies

Crispr Genomic Cure Market, By Targeted Genetic Modification:

  • Single Gene Modification
  • Multiple Gene Modification
  • Genome-wide Modification

Crispr Genomic Cure Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Crispr Genomic Cure Market.

Available Customizations:

Global Crispr Genomic Cure market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Crispr Genomic Cure Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type (Genetic Disorders, Cancer, Infectious Diseases, Neurological Disorders, Cardiovascular Disorders, Blood Disorders, Metabolic Disorders, Others)
    • 5.2.2. By Therapy Type (Gene Editing, Gene Therapy, Cell Therapy, Immunotherapy)
    • 5.2.3. By Delivery Method (In vivo, Ex vivo)
    • 5.2.4. By End User (Hospitals & Clinics, Research Institutes, Biotechnology & Pharmaceutical Companies)
    • 5.2.5. By Targeted Genetic Modification (Single Gene Modification, Multiple Gene Modification, Genome-wide Modification)
    • 5.2.6. By Region
    • 5.2.7. By Company (2024)
  • 5.3. Market Map

6. North America Crispr Genomic Cure Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Therapy Type
    • 6.2.3. By Delivery Method
    • 6.2.4. By End User
    • 6.2.5. By Targeted Genetic Modification
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Crispr Genomic Cure Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Therapy Type
        • 6.3.1.2.3. By Delivery Method
        • 6.3.1.2.4. By End User
        • 6.3.1.2.5. By Targeted Genetic Modification
    • 6.3.2. Canada Crispr Genomic Cure Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Therapy Type
        • 6.3.2.2.3. By Delivery Method
        • 6.3.2.2.4. By End User
        • 6.3.2.2.5. By Targeted Genetic Modification
    • 6.3.3. Mexico Crispr Genomic Cure Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Therapy Type
        • 6.3.3.2.3. By Delivery Method
        • 6.3.3.2.4. By End User
        • 6.3.3.2.5. By Targeted Genetic Modification

7. Europe Crispr Genomic Cure Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Therapy Type
    • 7.2.3. By Delivery Method
    • 7.2.4. By End User
    • 7.2.5. By Targeted Genetic Modification
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Crispr Genomic Cure Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Therapy Type
        • 7.3.1.2.3. By Delivery Method
        • 7.3.1.2.4. By End User
        • 7.3.1.2.5. By Targeted Genetic Modification
    • 7.3.2. United Kingdom Crispr Genomic Cure Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Therapy Type
        • 7.3.2.2.3. By Delivery Method
        • 7.3.2.2.4. By End User
        • 7.3.2.2.5. By Targeted Genetic Modification
    • 7.3.3. Italy Crispr Genomic Cure Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Therapy Type
        • 7.3.3.2.3. By Delivery Method
        • 7.3.3.2.4. By End User
        • 7.3.3.2.5. By Targeted Genetic Modification
    • 7.3.4. France Crispr Genomic Cure Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Disease Type
        • 7.3.4.2.2. By Therapy Type
        • 7.3.4.2.3. By Delivery Method
        • 7.3.4.2.4. By End User
        • 7.3.4.2.5. By Targeted Genetic Modification
    • 7.3.5. Spain Crispr Genomic Cure Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Disease Type
        • 7.3.5.2.2. By Therapy Type
        • 7.3.5.2.3. By Delivery Method
        • 7.3.5.2.4. By End User
        • 7.3.5.2.5. By Targeted Genetic Modification

8. Asia-Pacific Crispr Genomic Cure Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Therapy Type
    • 8.2.3. By Delivery Method
    • 8.2.4. By End User
    • 8.2.5. By Targeted Genetic Modification
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Crispr Genomic Cure Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Therapy Type
        • 8.3.1.2.3. By Delivery Method
        • 8.3.1.2.4. By End User
        • 8.3.1.2.5. By Targeted Genetic Modification
    • 8.3.2. India Crispr Genomic Cure Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Therapy Type
        • 8.3.2.2.3. By Delivery Method
        • 8.3.2.2.4. By End User
        • 8.3.2.2.5. By Targeted Genetic Modification
    • 8.3.3. Japan Crispr Genomic Cure Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Therapy Type
        • 8.3.3.2.3. By Delivery Method
        • 8.3.3.2.4. By End User
        • 8.3.3.2.5. By Targeted Genetic Modification
    • 8.3.4. South Korea Crispr Genomic Cure Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Disease Type
        • 8.3.4.2.2. By Therapy Type
        • 8.3.4.2.3. By Delivery Method
        • 8.3.4.2.4. By End User
        • 8.3.4.2.5. By Targeted Genetic Modification
    • 8.3.5. Australia Crispr Genomic Cure Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Disease Type
        • 8.3.5.2.2. By Therapy Type
        • 8.3.5.2.3. By Delivery Method
        • 8.3.5.2.4. By End User
        • 8.3.5.2.5. By Targeted Genetic Modification

9. South America Crispr Genomic Cure Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Therapy Type
    • 9.2.3. By Delivery Method
    • 9.2.4. By End User
    • 9.2.5. By Targeted Genetic Modification
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Crispr Genomic Cure Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Therapy Type
        • 9.3.1.2.3. By Delivery Method
        • 9.3.1.2.4. By End User
        • 9.3.1.2.5. By Targeted Genetic Modification
    • 9.3.2. Argentina Crispr Genomic Cure Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Therapy Type
        • 9.3.2.2.3. By Delivery Method
        • 9.3.2.2.4. By End User
        • 9.3.2.2.5. By Targeted Genetic Modification
    • 9.3.3. Colombia Crispr Genomic Cure Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Therapy Type
        • 9.3.3.2.3. By Delivery Method
        • 9.3.3.2.4. By End User
        • 9.3.3.2.5. By Targeted Genetic Modification

10. Middle East and Africa Crispr Genomic Cure Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Disease Type
    • 10.2.2. By Therapy Type
    • 10.2.3. By Delivery Method
    • 10.2.4. By End User
    • 10.2.5. By Targeted Genetic Modification
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Crispr Genomic Cure Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Disease Type
        • 10.3.1.2.2. By Therapy Type
        • 10.3.1.2.3. By Delivery Method
        • 10.3.1.2.4. By End User
        • 10.3.1.2.5. By Targeted Genetic Modification
    • 10.3.2. Saudi Arabia Crispr Genomic Cure Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Disease Type
        • 10.3.2.2.2. By Therapy Type
        • 10.3.2.2.3. By Delivery Method
        • 10.3.2.2.4. By End User
        • 10.3.2.2.5. By Targeted Genetic Modification
    • 10.3.3. UAE Crispr Genomic Cure Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Disease Type
        • 10.3.3.2.2. By Therapy Type
        • 10.3.3.2.3. By Delivery Method
        • 10.3.3.2.4. By End User
        • 10.3.3.2.5. By Targeted Genetic Modification

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Crispr Genomic Cure Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Merck KGaA
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Takara Bio Inc
  • 14.3. Lonza Group AG
  • 14.4. Horizon Discovery Group Ltd
  • 14.5. Genscript Biotech Corp
  • 14.6. Synthego Corp
  • 14.7. Precision BioSciences Inc
  • 14.8. Mammoth Biosciences Inc
  • 14.9. Thermo Fisher Scientific Inc
  • 14.10.Intellia Therapeutics Inc.

15. Strategic Recommendations

16. About Us & Disclaimer